Technetium-99m glucoheptonate in brain-tumor detection: an important advance in radiotracer techniques.
We have compared [Tc-99m] sodium pertechnetate with Tc-99m glucoheptonate in 52 patients studied for various brain lesions. Flow studies as well as delayed scans were performed in all. Especially in primary and metastatic lesions of the posterior fossa, the diagnostic yield was improved by the delayed glucoheptonate (GH) scans. In contrast, no advantage of GH over pertechnetate could be detected in the study of infarcts or other ischemic lesions. Various hypotheses are discussed to explain the observed differences in behavior between the two tracers.
D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000000981:diagnostic imaging*; D005260:Female; D006539:Heptoses / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011877:Radionuclide Imaging / Q000379:methods; D013400:Sugar Acids / Q000378:metabolism; D013667:Technetium
D006539:Heptoses; D013400:Sugar Acids; D013667:Technetium; C007852:alpha-glucoheptonic acid